KLBF – To disburse 45-55% of 2023 net profit as dividend

KLBF – To disburse 45-55% of 2023 net profit as dividend Kalbe Farma (KLBF) posted sales of IDR24.23 tn (+7.40% yoy) and net profit of IDR2.37 tn (+15.20% yoy) in 9M24. KLBF's sales consisted of the prescription drug segment at IDR6.25 tn (+10.40% yoy), the health products segment at IDR2.74 tn (+4.00% yoy), the nutrition segment at IDR6 tn (+2.80% yoy) and the distribution and logistics segment at IDR7.86 tn (+12.60% yoy). KLBF's domestic sales also increased by 8.40% yoy, although export sales decreased by 7.40% yoy. The decline in export sales was due to political instability, restrictions on import permits in destination countries and weakening purchasing power. Moreover, KLBF has built an ecosystem of oncology, biologic drugs, generic drugs and medical devices in the last 9 months. KLBF targets sales growth of 6-7% yoy and net profit of 13-15% yoy in 2024. KLBF also will disburse 45-55% of the 2023 net profit as dividends. (Source : Bisnis Indonesia)